Key facts
- It has raised $13.7M across 3 recorded rounds; the latest was Seed Round ($1.5M) in May 2019.
- Notable investors include National Institutes of Health, Alsora Capital, GRA Venture Fund, Masters Capital Management.
- BioCircuit Technologies has filed 3 Form Ds with the SEC since 2021, most recently Oct 2022 ($9.0M sold to 33 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for BioCircuit Technologies
Funding rounds
3 roundsAbout BioCircuit Technologies
Manufacturer of medical devices designed to monitor and control peripheral nerve activity. The company's devices leverage multi-electrode arrays and proprietary algorithms for repairing peripheral nerves, providing clinicians with a practical ability to diagnose health conditions earlier, track the progression of symptoms over time, and select treatments more precisely for individual patients.
- Sector
- Healthcare
- HQ
- Atlanta, GA, United States
- Founded
- 2016
- Employees
- 34
- Website
- biocircuit.com/
- Ownership
- Privately Held (backing)
BioCircuit Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in BioCircuit Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on BioCircuit Technologies in its N-PORT filings yet. We sweep new filings monthly.